Ventyx Biosciences, Inc.

Equities

VTYX

US92332V1070

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-06-18 EDT			5-day change	1st Jan Change
2.75 ^USD	0.00%		-14.06%	+11.34%

06-11	Transcript : Ventyx Biosciences, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 08:40 AM
06-06	Oppenheimer Adjusts Ventyx Biosciences Price Target to $10 From $12, Maintains Outperform Rating	MT

Ventyx Biosciences, Inc. acquired Zomagen Biosciences Ltd.

April 13, 2023

Ventyx Biosciences, Inc. (NasdaqGS:VTYX) acquired Zomagen Biosciences Ltd on February 26, 2021.

Ventyx Biosciences, Inc. (NasdaqGS:VTYX) completed the acquisition of Zomagen Biosciences Ltd on February 26, 2021.

Latest news about Ventyx Biosciences, Inc.

Transcript : Ventyx Biosciences, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 08:40 AM	06-11
Oppenheimer Adjusts Ventyx Biosciences Price Target to $10 From $12, Maintains Outperform Rating	06-06	MT
Ventyx Biosciences Preclinical Study of Obesity Control Candidate Shows Positive Results	06-05	MT
Ventyx Biosciences, Inc. Announces Positive Preclinical Data for CNS-Penetrant NLRP3 Inhibitor VTX3232 Demonstrating Reversal of Obesity and Improvements in Cardiometabolic and Inflammatory Markers	06-05	CI
Transcript : Ventyx Biosciences, Inc. Presents at UBS Obesity Therapeutics Day, May-23-2024 12:00 PM	05-23
Ventyx Biosciences Appoints Matthew Moore as Chief Operating Officer; Shares Rise	05-16	MT
Ventyx Biosciences Announces Appointment of Matthew Moore as Chief Operating Officer	05-16	CI
Transcript : Ventyx Biosciences, Inc., Q1 2024 Earnings Call, May 09, 2024	05-09
Ventyx Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
Ventyx Biosciences, Inc. Announces Resignation of Christopher Krueger as Chief Business Officer, Effective on April 15, 2024	04-05	CI
Transcript : Ventyx Biosciences, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-14-2024 10:45 AM	03-14
Canaccord Genuity Trims Price Target on Ventyx Biosciences to $15 From $16, Maintains Buy Rating	03-13	MT
North American Morning Briefing : Stock Futures -2-	03-13	DJ
Ventyx Biosciences Shares Rise After Oppenheimer, Wells Fargo Upgrades	03-12	MT
Oppenheimer Upgrades Ventyx Biosciences to Outperform From Perform, $12 Price Target	03-12	MT
Wells Fargo Upgrades Ventyx Biosciences to Overweight From Equal Weight, Raises Price Target to $16 From $7	03-12	MT
Canaccord Genuity Adjusts Ventyx Biosciences' Price Target to $16 From $20, Maintains Buy Rating	03-11	MT
Transcript : Ventyx Biosciences, Inc. - Special Call	03-11
Ventyx Biosciences, Inc. Reports Clinical Data for Its NLRP3 Inhibitor Portfolio and Provides Pipeline Updates at Virtual Investor Event	03-11	CI
Ventyx Biosciences, Inc. announced that it expects to receive $100.0073 million in funding	03-05	CI
Lifesci Capital Upgrades Ventyx Biosciences to Outperform From Market Perform, $5 Price Target	02-28	MT
Ventyx Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-27	CI
Ventyx Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-27	CI
Wells Fargo Cuts Ventyx Biosciences Price Target to $3 From $8, Maintains Equal Weight Rating	12-19	MT
Stifel Adjusts Price Target on Ventyx Biosciences to $2 From $6, Maintains Hold Rating	12-18	MT

Chart Ventyx Biosciences, Inc.

Duration

Period

More charts

Company Profile

Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of small molecule product candidates to address a range of inflammatory diseases with unmet need. The Companyâs pipeline includes VTX002 (S1P1R Modulator), VTX958 (TYK2 Inhibitor), and VTX2735 and VTX3232 (NLRP3 Inhibitor Portfolio). VTX002 is a sphingosine 1 phosphate receptor (S1P1R) modulator in Phase II development for patients with moderately to severely active ulcerative colitis (UC). VTX958 is an oral, selective clinical-stage inhibitor of tyrosine kinase type 2 (TYK2), an intracellular signaling kinase in the Janus kinase (JAK) family that regulates chronic inflammation in immune-mediated diseases. Its third product candidate, VTX2735, is a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor. In addition to VTX2735, it is also developing VTX3232, its lead CNS-penetrant NLRP3 inhibitor in Phase 1 development.

Sector

Biotechnology & Medical Research

Calendar

2024-08-11 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.75 USD

Average target price

10.8 USD

Spread / Average Target

+292.73%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VENTYX BIOSCIENCES, INC.	+11.34%	194M
VERTEX PHARMACEUTICALS INCORPORATED	+14.84%	121B
REGENERON PHARMACEUTICALS, INC.	+18.31%	112B
ARGENX SE	+2.94%	22.72B
BIONTECH SE	-18.26%	20.82B
GENMAB A/S	-18.47%	16.66B
WUXI APPTEC CO., LTD.	-42.36%	16.36B
BEIGENE, LTD.	-14.23%	16.19B
NEUROCRINE BIOSCIENCES, INC.	-0.68%	13.17B
SAREPTA THERAPEUTICS, INC.	+21.87%	11.11B

Bio Therapeutic Drugs